In an endeavour to create awareness about the latest techniques and treatments available for prostate cancer, Medanta – The Medicity today organized a scientific program on “Update in Management of Carcinoma Prostate.” The theme was to highlight the changing focus towards curative intent for localized as well as advanced and metastatic disease. Over 125 Surgeons, Physicians, Urologists, Radiation and Medical Oncologists from India and abroad participated in the unique conference. The program has been organized to mark the beginning of World Prostate Disease Month (September) and was headed by Dr. N.P. Gupta, Chairman, Kidney and Urology Institute, Medanta- The Medicity.
September is observed as Prostate Cancer awareness month and camps are conducted worldwide to spread awareness. With increase in life expectancy, adoption of newer lifestyles and screening using prostate specific antigen (PSA), the incidence of prostate cancer is on the rise. As per records of cancer registries maintained in different towns in India, the newly diagnosed cases of cancer prostate are increasing by 1% every year. In Delhi NCR cancer registry, it has become the second most common cancer in men, next only to lung cancer.
Fifty-one faculty doctors and 75 delegates actively participated in the Update, which focused on understanding the management of Prostate Cancer and improving patient care in a cost effective way. Various topics were discussed like the role of radical prostatectomy, role of chemo-hormonal therapy, and how to define CRPC amongst others. Owing to better understanding of the disease and advances in treatment modalities, focus is changing from palliation to curative intent for localized, locally advanced and metastatic disease. This is achieved by multimodality treatment including surgery, radiation, hormonal treatment, chemotherapy and molecular targeted therapy.
Speaking on the occasion, Dr. N.P. Gupta said, “In India, Prostate Cancer is the second most common cancer in males. Lately we have been witnessing that younger population is also being diagnosed with this disease. The advancements that have been made in the past decade have given us a chance to understand and help the patients of carcinoma prostate in a much better way. The different types of scientific tools and diagnostic methods will help us to provide a better care for our patients. We hope that the initiative will help in educating the doctors and guide them in their practices, in order to perform a safe surgery along with wholesome management and minimum complications.”
We love to hear about our doctors, facilities
and your treatment at Medanta.
The User agrees and acknowledges that the User has read, understood and accepts the terms and conditions contained in the brochure provided with the Device (“Device”) with respect to its usage, operations, return / replacement and warranty policy.
The User hereby agrees and acknowledges that the Device (hardware and software) used in the provision
of services by Medanta is being provided on “as is” and “as available” basis through Alivecor India Private
Limited. Neither does Medanta endorse or promote the Device in any manner nor will Medanta be liable
for any claims, representations or warranties, whether express or implied as to the safety, reliability,
durability and performance of the device.
The services once availed cannot be cancelled except in cases where the User requests to cancel the service on the day of purchase in which case, full amount of service fees shall be refunded to the User provided that the Device has not been unboxed.
Before the expiry of service duration, the User can extend the services by availing various program options. For the said purposes, the User can call our helpline number +91 124 4141414 or visit www.medanta.org. The extended program availed by the User shall be activated automatically on expiry of existing program of services.
In cases where the User has opted for availing the Services through rented Device, a refundable deposit amount of ₹ 5,000 (“Deposit Amount”) shall be applicable and paid by the User. The refund of Deposit Amount shall be subject to return of the Device in working and undamaged condition. Refund of Deposit Amount shall be made through the same mode of payment as that of purchase in cases where the User personally visits the Medanta for returning the Device. If the User opts to return the Device through post, Deposit Amount shall be refunded electronically thorough NEFT or Bank transfer by Medanta within seven (7) working days of receipt of the Device and receipt of scanned image/copy of the ‘Cancelled Cheque’ of the User’s bank account.
Upon expiry of the services (either in terms of number of ECG or duration of the program) availed by the
User, the Device has to be returned within ten (10) days failing which the Deposit Amount shall be
Please note that the ECG pack or Refundable Device deposit are non-transferable from one patient to another.